

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10587819	
	Filing Date		2006-07-28	
	First Named Inventor	Anil CHAUHAN		
	Art Unit	1644		
	Examiner Name	Francois VANDERVEGT		
	Attorney Docket Number	60020200-0011		

U.S.PATENTS						
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Patent citation information please click the Add button.

U.S.PATENT APPLICATION PUBLICATIONS						
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Published Application citation information please click the Add button.

FOREIGN PATENT DOCUMENTS								
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² j	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1	WO/2003/012396	WO		2003-02-13	Anil CHAUHAN		<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

NON-PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10587819
Filing Date	2006-07-28
First Named Inventor	Anil CHAUHAN
Art Unit	1644
Examiner Name	Francois VANDERVEGT
Attorney Docket Number	60020200-0011

1	AFANASYEVA and ROSE, Cardomyopathy is linked to complement activation, Am J Pathol, 2002, p 351-7, vol 161.	<input type="checkbox"/>
2	BOHANA-KASHTAN et al, Cell signals transduced by complement, Mol Immunol, 2004, p 583-97, vol 41.	<input type="checkbox"/>
3	COUSER, Mediation of immune glomerular injury, J Am Soc Nephrol, 1990, p 13-29, vol 1.	<input type="checkbox"/>
4	CYBULSKY et al, Complement C5b-9 induces receptor tyrosine kinase transactivation in glomerular epithelial cells, Am J Pathol, p 1701-11, vol 155.	<input type="checkbox"/>
5	CZERMAK et al, Synergistic enhancement of chemokine generation and lung injury by C5a or the membrane attack complex of complement, Am J Pathol, 1999, p 1513-24, vol 154.	<input type="checkbox"/>
6	HALPERIN et al, Terminal compliment complex C5b-9 stimulates mitogenesis in 3T3 cells, 1993, p 1974-8, vol 91	<input type="checkbox"/>
7	MUKHERJEE and PASINETTI, Complement anaphyatoxin C5a neuroprotects through mitogen-activated protein kinase-dependent inhibition of caspase 3, J Neurochem, 2001, p 43-9, vol 77.	<input type="checkbox"/>
8	NICULESCU et al, Activation of Ras and mitogen-activated protein kinase pathway by terminal complement complexes is G protein dependent, J Immunol, 1997, p 4405-12, vol 158.	<input type="checkbox"/>
9	NICULESCU et al, Receptor-independent activation of guanine nucleotide-binding regulatory proteins by terminal complement complexes, 1994, p 4417-23, vol 269.	<input type="checkbox"/>
10	PIPPIN et al, DNA damage is a novel response to sublytic complement C5b-9-induced injury in podocytes, J Clin Invest, 2003, p 877-85, vol 111.	<input type="checkbox"/>
11	RUS et al, Sublytic complement attack induces cell cycle in oligodendrocytes, 1996, p 4892-900, vol 156	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10587819
Filing Date	2006-07-28
First Named Inventor	Anil CHAUHAN
Art Unit	1644
Examiner Name	Francois VANDERVEGT
Attorney Docket Number	60020200-0011

12	SHIRAZI et al, Release of leukotriene B4 from sublethally injured oligodendrocytes by terminal complement complexes, 1987, p 271-8. vol 48.	<input type="checkbox"/>
13	VAKEVA et al, Myocardial infarction and apoptosis after myocardial ischemia and reperfusion: role of the terminal complement components and inhibitions by anti-C5 therapy, Circulation, 1998, p 2259-67, vol 97.	<input type="checkbox"/>
14	VIEDT et al, The terminal complement complex C5b-9 stimulates interleukin-6 production in human smooth muscle cells through activation of transcription factors NF-kappa B and AP-1, 2000, p 2370-2, vol 14.	<input type="checkbox"/>
15	WALPORT, Complement and systemic lupus erythematosus, Arthritis Res, 2002, p S279-93, vol 4 supp 3.	<input type="checkbox"/>
16	YASOJIMA et al, Generation of C-reactive protein and complement components in atherosclerotic plaques, Am J Pathol, 1999, p 1039-51, vol 158.	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.